Cogent Biosciences (COGT) Competitors $7.22 -0.20 (-2.70%) As of 10:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock COGT vs. LYEL, APLS, OGN, HCM, IBRX, AMRX, XENE, MIRM, ARWR, and AAPGShould you be buying Cogent Biosciences stock or one of its competitors? The main competitors of Cogent Biosciences include Lyell Immunopharma (LYEL), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), HUTCHMED (HCM), ImmunityBio (IBRX), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Mirum Pharmaceuticals (MIRM), Arrowhead Pharmaceuticals (ARWR), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Cogent Biosciences vs. Lyell Immunopharma Apellis Pharmaceuticals Organon & Co. HUTCHMED ImmunityBio Amneal Pharmaceuticals Xenon Pharmaceuticals Mirum Pharmaceuticals Arrowhead Pharmaceuticals Ascentage Pharma Group International Cogent Biosciences (NASDAQ:COGT) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings. Do analysts rate COGT or LYEL? Cogent Biosciences currently has a consensus target price of $14.57, suggesting a potential upside of 101.82%. Lyell Immunopharma has a consensus target price of $20.00, suggesting a potential upside of 95.12%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cogent Biosciences is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cogent Biosciences 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Which has more volatility & risk, COGT or LYEL? Cogent Biosciences has a beta of 1.82, indicating that its share price is 82% more volatile than the S&P 500. Comparatively, Lyell Immunopharma has a beta of -0.26, indicating that its share price is 126% less volatile than the S&P 500. Does the media refer more to COGT or LYEL? In the previous week, Lyell Immunopharma had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 7 mentions for Lyell Immunopharma and 5 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.32 beat Lyell Immunopharma's score of 0.44 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lyell Immunopharma 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer COGT or LYEL? Cogent Biosciences received 278 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 70.02% of users gave Cogent Biosciences an outperform vote while only 43.75% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformCogent BiosciencesOutperform Votes29270.02% Underperform Votes12529.98% Lyell ImmunopharmaOutperform Votes1443.75% Underperform Votes1856.25% Do insiders and institutionals hold more shares of COGT or LYEL? 66.1% of Lyell Immunopharma shares are owned by institutional investors. 5.9% of Cogent Biosciences shares are owned by insiders. Comparatively, 25.1% of Lyell Immunopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, COGT or LYEL? Cogent Biosciences has higher earnings, but lower revenue than Lyell Immunopharma. Cogent Biosciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCogent BiosciencesN/AN/A-$192.41M-$1.84-3.92Lyell Immunopharma$65K2,335.11-$234.63M-$25.00-0.41 Is COGT or LYEL more profitable? Cogent Biosciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Cogent Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cogent BiosciencesN/A -112.55% -60.44% Lyell Immunopharma -323,792.09%-34.64%-30.02% SummaryCogent Biosciences beats Lyell Immunopharma on 12 of the 18 factors compared between the two stocks. Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COGT vs. The Competition Export to ExcelMetricCogent BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$822.04M$6.85B$5.58B$8.67BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-2.918.8227.2320.12Price / SalesN/A263.82423.64161.29Price / CashN/A65.8538.2534.64Price / Book3.146.657.114.72Net Income-$192.41M$143.49M$3.23B$247.80M7 Day Performance28.01%4.70%3.67%2.77%1 Month Performance49.17%15.02%13.11%9.75%1 Year Performance-18.14%5.96%32.12%15.01% Cogent Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COGTCogent Biosciences1.6056 of 5 stars$7.22-2.7%$14.57+101.8%-13.7%$822.04MN/A-2.9180Positive NewsLYELLyell Immunopharma2.1802 of 5 stars$8.22-5.9%$1.00-87.8%-77.1%$2.43B$65,000.00-10.40270High Trading VolumeAPLSApellis Pharmaceuticals4.6571 of 5 stars$19.14+13.1%$40.05+109.3%-53.0%$2.41B$775.84M-9.43770Analyst RevisionHigh Trading VolumeOGNOrganon & Co.4.9261 of 5 stars$9.22-0.1%$18.00+95.3%-51.5%$2.40B$6.29B2.7710,000Trending NewsHCMHUTCHMED1.2799 of 5 stars$13.60-2.1%$19.00+39.7%-6.9%$2.37B$630.20M0.001,760Upcoming EarningsIBRXImmunityBio1.9585 of 5 stars$2.67+0.4%$12.25+358.8%-46.5%$2.36B$31.22M-2.90590High Trading VolumeAMRXAmneal Pharmaceuticals3.716 of 5 stars$7.42+1.4%$11.50+55.0%+14.0%$2.33B$2.83B-10.917,600Positive NewsXENEXenon Pharmaceuticals3.4834 of 5 stars$30.07+4.2%$54.82+82.3%-15.9%$2.31B$7.50M-10.66210Analyst RevisionMIRMMirum Pharmaceuticals2.9102 of 5 stars$45.97+3.4%$60.73+32.1%+91.7%$2.28B$379.25M-22.76140Positive NewsAnalyst RevisionARWRArrowhead Pharmaceuticals3.7308 of 5 stars$16.40+2.1%$42.13+156.9%-30.8%$2.26B$545.21M-3.17400Analyst RevisionAAPGAscentage Pharma Group InternationalN/A$25.22+3.4%N/AN/A$2.20B$980.65M0.00600 Related Companies and Tools Related Companies Lyell Immunopharma Alternatives Apellis Pharmaceuticals Alternatives Organon & Co. Alternatives HUTCHMED Alternatives ImmunityBio Alternatives Amneal Pharmaceuticals Alternatives Xenon Pharmaceuticals Alternatives Mirum Pharmaceuticals Alternatives Arrowhead Pharmaceuticals Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COGT) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COGT Stock Free COGT Stock Alerts